Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ImmunityBio, Inc.
Ohio State University Comprehensive Cancer Center
Bristol-Myers Squibb
Yale University
National Cancer Institute (NCI)
Celgene
University of Kentucky
Centre hospitalier de l'Université de Montréal (CHUM)
Lung Cancer Group Cologne
Wake Forest University Health Sciences
H. Lee Moffitt Cancer Center and Research Institute
Jules Bordet Institute
MultiVir, Inc.